Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
The Povorcitinib for Vitiligo clinical trial, sponsored by Incyte Corporation, is a Phase 3 study evaluating the efficacy and safety of povorcitinib, a Janus Kinase (JAK) inhibitor, in adults with non-segmental vitiligo. The trial aims to determine if povorcitinib can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.
Key Details
- Study Type: Interventional (Clinical Trial)
- Phase: Phase 3
- Estimated Enrollment: Not Specified
- Age Range: 18 years and older
- Duration: Approximately 104 weeks, including treatment and follow-up periods
This study has 102 locations across USA, Canada, Belgium, France, Gemany, Japan, Mexico, Netherlands, Poland and Spain.
For more information about eligibility criteria and study locations, please visit the official clinical trial page on ClinicalTrials.gov (NCT06113445) or contact the study team directly.
The VRF will continue to monitor the progress of this trial and provide updates as they become available. We encourage eligible individuals to consider participating in this important research effort to advance vitiligo treatment.
Start date: 2023-11-27
Completion date: 2026-05-18
Contact: Incyte Corporation Call Center
Tel.: 1-855-463-3463
Email: medinfo@incyte.com
Link: https://clinicaltrials.gov/study/NCT06113445
FAQOther Questions
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
- How can I cure vitiligo?
Currently, there is no cure for vitiligo. However, many treatments can help manage the condition by restoring skin pigmentation, halting the progression of depigmentation, and i...
- What's the status with official recognition of World Vitiligo Day?
In 2016, the United Nations marked World Vitiligo Day in its International Calendar of Disability Events. However, it was removed in 2019 when the calendar was streamlined to 'M...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.